As of early 2026, the global oncology and nuclear medicine sectors are witnessing a fundamental paradigm shift, with the Radiopharmaceutical Market emerging as a primary frontier for precision medicine. The transition from diagnostic-only tracers to integrated "theranostic" pairs—where the same molecular targeting agent is used for both imaging and high-energy therapeutic...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Italiano
Romaian
Portuguese (Brazil)
china